Evaluation of the effect of nano micelles containing curcumin (Sina Ccurcumin) as a therapeutic supplement in patients with COVID-19
- Conditions
- COVID-19.COVID-19, virus identified• U07.1
- Registration Number
- IRCT20200611047735N1
- Lead Sponsor
- Bandare-abbas University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Laboratory-approved COVID-19 tests (2019-nCoV Real-Time RT-PCR) (preferably at a particular center or university-approved center) regardless of clinical manifestations and close contact history
Signing a written consent form
No simultaneous participation in other clinical trials
Pregnancy and lactation
History of allergy to turmeric or curcumin products
Smoking (more than 5 cigarettes a day)
Patient connected to the ventilator
Clinical evidence for respiratory failure at the time of hospitalization / admission (SaO2 = 90% or PaO2 <8 kPa)
Having comorbidities (such as severe renal failure Glomerular filtration rate less than 30 ml / min, liver failure ,Congestive heart failure, or Chronic obstructive pulmonary disease)
History of gallstones
History of gastritis or active gastrointestinal ulcer
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical symptoms. Timepoint: On a weekly basis, patients are examined clinically on days 1, 7, and 14. Method of measurement: Clinical examinations.;Immune cell balance. Timepoint: On a weekly basis, blood samples are taken from patients and patients are examined on days 1, 7 and 14. Method of measurement: Molecular experiments.
- Secondary Outcome Measures
Name Time Method